A Randomized Double-blind Placebo controlled Multi-center 2-part Phase 2 Study to Evaluate Efficacy Safety and Tolerability of RGH-706 in Prader-Willi Syndrome

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Prader-willi Syndrome
  • Age: Between 17 Year(s) - 65 Year(s)
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. Genetically confirmed diagnosis of PWS
    2. Body weight =40 kg/88 lbs and ≤200 kg/450 lbs
    3. Stable body weight, self or caregiver-reported weight change ≤5% in the previous 3 months.
    4. If a patient has a cu

You may not be eligible for this study if the following are true:

    1. Hypersensitivity to RGH-706 or any of the excipients (gelatin, starch, or magnesium stearate)
    2. Severe psychiatric disorders (eg, schizophrenia, bipolar disorder, or major depressive disorder), recent (within 6 months) psychotic or


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.